Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine for Prevention of Chemotherapy-Induced Peripheral Neuropathy
NCT05875610Phase 4Unknown
- Sponsor
- Mit Ghamr Oncology Center
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of venlafaxine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Mit Ghamr Oncology Center. Primary endpoint: Incidence of grade II or more peripheral neuropathy at 4 months. Status: unknown.
02
Drugs
venlafaxine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05875610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875610.